9,121 Shares in BridgeBio Pharma, Inc. $BBIO Purchased by University of Texas Texas AM Investment Management Co.

University of Texas Texas AM Investment Management Co. purchased a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 9,121 shares of the company’s stock, valued at approximately $394,000.

A number of other hedge funds also recently made changes to their positions in BBIO. GAMMA Investing LLC increased its position in BridgeBio Pharma by 71.0% during the 1st quarter. GAMMA Investing LLC now owns 920 shares of the company’s stock worth $32,000 after buying an additional 382 shares during the period. Jones Financial Companies Lllp acquired a new position in BridgeBio Pharma during the 1st quarter worth approximately $35,000. GF Fund Management CO. LTD. boosted its holdings in shares of BridgeBio Pharma by 22.0% during the 1st quarter. GF Fund Management CO. LTD. now owns 4,839 shares of the company’s stock valued at $167,000 after acquiring an additional 871 shares in the last quarter. CWM LLC grew its holdings in shares of BridgeBio Pharma by 12.8% during the first quarter. CWM LLC now owns 5,261 shares of the company’s stock worth $182,000 after purchasing an additional 598 shares during the last quarter. Finally, LVW Advisors LLC acquired a new position in BridgeBio Pharma in the 2nd quarter valued at approximately $202,000. 99.85% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at BridgeBio Pharma

In other BridgeBio Pharma news, Director Charles J. Homcy sold 250,000 shares of BridgeBio Pharma stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $46.05, for a total transaction of $11,512,500.00. Following the transaction, the director directly owned 966,674 shares of the company’s stock, valued at approximately $44,515,337.70. This trade represents a 20.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Frank Mccormick sold 74,000 shares of the business’s stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $53.16, for a total value of $3,933,840.00. Following the completion of the sale, the director owned 83,275 shares of the company’s stock, valued at $4,426,899. The trade was a 47.05% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 597,913 shares of company stock valued at $29,034,227. 18.20% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Jefferies Financial Group initiated coverage on BridgeBio Pharma in a research note on Monday, July 14th. They set a “buy” rating and a $70.00 target price for the company. Wall Street Zen upgraded BridgeBio Pharma from a “sell” rating to a “hold” rating in a report on Saturday, August 9th. JPMorgan Chase & Co. upped their price objective on shares of BridgeBio Pharma from $55.00 to $70.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 3rd. Citigroup lifted their target price on BridgeBio Pharma from $58.00 to $67.00 and gave the stock a “buy” rating in a research note on Friday, July 11th. Finally, Oppenheimer increased their price objective on BridgeBio Pharma from $60.00 to $61.00 and gave the company an “outperform” rating in a report on Wednesday, August 6th. Sixteen research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, BridgeBio Pharma has an average rating of “Moderate Buy” and a consensus target price of $65.25.

BridgeBio Pharma Trading Up 0.8%

BBIO stock opened at $54.26 on Friday. BridgeBio Pharma, Inc. has a 1-year low of $21.72 and a 1-year high of $57.49. The stock has a market cap of $10.37 billion, a price-to-earnings ratio of -13.27 and a beta of 1.36. The company’s 50 day moving average is $52.42 and its 200 day moving average is $44.47.

BridgeBio Pharma (NASDAQ:BBIO) last announced its earnings results on Tuesday, August 5th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.12). The company had revenue of $110.57 million for the quarter, compared to the consensus estimate of $98.46 million. During the same period in the previous year, the business earned ($0.39) EPS. The business’s quarterly revenue was up 4999.9% compared to the same quarter last year. As a group, sell-side analysts forecast that BridgeBio Pharma, Inc. will post -3.67 EPS for the current fiscal year.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.